Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
Completed
Anavex Life Sciences Corp.
Phase 2
The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of
ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary
objectives being to explore the relationship between dosing regimen and pharmacodynamics
efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore
the relationship of ANAVEX2-73 as add-on therapy to AD standard of care.
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Completed
Anavex Life Sciences Corp.
Phase 2
This open label extension study is designed to provide continued access to ANAVEX 2-73 for
eligible subjects with mild to moderate Alzheimer's Disease who have previously participated
in the Anavex sponsored study ANAVEX2-73-002.
Study of ANAVEX2-73 in Patients With Rett Syndrome
Completed
International Rett Syndrome Foundation Rettsyndrome.org
Phase 2
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized,
placebo-controlled study.
7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients
with RTT 18 years or older. A voluntary option will be offered for all patients who meet the
exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Study of ANAVEX2-73 in Patients With Rett Syndrome
Completed
Anavex Life Sciences Corp.
Phase 2
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized,
placebo-controlled study.
7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients
with RTT 18 years or older. A voluntary option will be offered for all patients who meet the
exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
